Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 52

  • 1 201 clinical trials
  • 458 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia77Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Follicular lymphoma41Plasma cell myeloma refractory41Mantle cell lymphoma32Myelofibrosis31Chronic myeloid leukaemia29B-cell small lymphocytic lymphoma28Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17B-cell lymphoma refractory16B-cell type acute leukaemia16Paroxysmal nocturnal haemoglobinuria16Diffuse large B-cell lymphoma refractory14+340

Clinical trials in Blood and lymphatic system disorders

1 201 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 201 clinical trials

Sickle cell anaemia with crisis

Not recruiting

Study on the Safety and Effectiveness of CSL889 for Adults and Adolescents with Sickle Cell Disease During Painful Crises

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:HEMOPEXIN, HUMAN
  • Sponsor:CSL Behring LLC

Primary myelofibrosis

Not recruiting

Study of Momelotinib and Luspatercept for Patients with Transfusion-Dependent Myelofibrosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Glaxosmithkline Research & Development Limited

Acute myeloid leukaemia+1

Not recruiting

Study of Natural Killer Cells and Aldesleukin for Patients with Acute Myeloid Leukemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Stichting Radboud University Medical Center

Hairy cell leukaemia+1

Not recruiting

Study of Obinutuzumab, Vemurafenib, and Cobimetinib for Hairy Cell Leukemia in Patients Previously Treated with Purine Analogs or Unfit for Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cobimetinib
  • Sponsor:Universita Degli Studi Di Perugia

Acute myeloid leukaemia refractory+3

Not recruiting

Study of S227928 Alone and with Venetoclax for Patients with Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Allopurinol
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Chronic lymphocytic leukaemia

Not recruiting

Study on the Effectiveness and Safety of Sonrotoclax and Zanubrutinib for Adults with Untreated Chronic Lymphocytic Leukemia

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib
  • Sponsor:BeOne Medicines AG

Mastocytosis

Not recruiting

Study on the Effectiveness and Safety of Masitinib for Patients with Severe Systemic Mastocytosis Unresponsive to Treatment

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Masitinib
  • Sponsor:Ab Science

Hodgkin's disease refractory+1

Not recruiting

Study of Ruxolitinib with Brentuximab or Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Universita Degli Studi Di Perugia

Plasma cell myeloma

Not recruiting

Study on Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Universita' Degli Studi Di Torino

Chronic lymphocytic leukaemia+1

Not recruiting

Study of Lisaftoclax and Acalabrutinib for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Ascentage Pharma Group Inc.

Acute myeloid leukaemia

Not recruiting

Study of Venetoclax and Decitabine for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Decitabine
  • Sponsor:Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare

Anaplastic large cell lymphoma T- and null-cell types

Not recruiting

Study of Lorlatinib for Patients with ALK+ Anaplastic Large Cell Lymphoma After Ineffective ALK Inhibitor Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lorlatinib
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab122 clinical trialsVenetoclax114 clinical trialsCyclophosphamide100 clinical trialsLenalidomide98 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.